|
1
|
Cancer Research UK: Statistics 2012–2013.
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer.
|
|
2
|
Amin MB, McKenney JK, Paner GP, Hansel DE,
Grignon DJ, Montironi R, Lin O, Jorda M, Jenkins LC, Soloway M, et
al International Consultation on Urologic Disease-European
Association of Urology Consultation on Bladder Cancer 2012:
ICUD-EAU international consultation on bladder cancer 2012:
Pathology. Eur Urol. 63:16–35. 2013. View Article : Google Scholar
|
|
3
|
Madersbacher S, Hochreiter W, Burkhard F,
Thalmann GN, Danuser H, Markwalder R and Studer UE: Radical
cystectomy for bladder cancer today -a homogeneous series without
neoadjuvant therapy. J Clin Oncol. 21:690–696. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Advanced Bladder Cancer Meta-analysis
Collaboration: Neoadjuvant chemotherapy for invasive bladder
cancer. Cochrane Database Syst Rev. 12004.
|
|
5
|
Leow JJ, Martin-Doyle W, Rajagopal PS,
Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL,
Choueiri TK, et al: Adjuvant chemotherapy for invasive bladder
cancer: A 2013 updated systematic review and meta-analysis of
randomized trials. Eur Urol. 66:42–54. 2014. View Article : Google Scholar
|
|
6
|
Loehrer PJ Sr, Einhorn LH, Elson PJ,
Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R,
Sarosdy MF, Lowe BA, et al: A randomized comparison of cisplatin
alone or in combination with methotrexate, vinblastine, and
doxorubicin in patients with metastatic urothelial carcinoma: A
cooperative group study. J Clin Oncol. 10:1066–1073. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multicenter, phase III study. J Clin Oncol. 18:3068–3077. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Necchi A, Pond GR, Giannatempo P, Di
Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A,
Vaishampayan UN, et al: Cisplatin-based first-line therapy for
advanced urothelial carcinoma after previous perioperative
cisplatin-based therapy. Clin Genitourin Cancer. 13:178–184. 2015.
View Article : Google Scholar :
|
|
9
|
Bellmunt J, von der Maase H, Mead GM,
Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C,
Paz-Ares L, Laufman LR, et al: Randomized phase III study comparing
paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in
patients with locally advanced or metastatic urothelial cancer
without prior systemic therapy: EORTC Intergroup Study 30987. J
Clin Oncol. 30:1107–1113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carles J, Esteban E, Climent M, Font A,
Gonzalez-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat
X, Albanell J, et al Spanish Oncology Genito Urinary Group Study
Group: Gemcitabine and oxaliplatin combination: A multicenter phase
II trial in unfit patients with locally advanced or metastatic
urothelial cancer. Ann Oncol. 18:1359–1362. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
De Santis M, Bellmunt J, Mead G, Kerst JM,
Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R and Sylvester
R: Randomized phase II/III trial assessing gemcitabine/carboplatin
and methotrexate/carboplatin/vinblastine in patients with advanced
urothelial cancer 'unfit' for cisplatin-based chemotherapy: Phase
II -results of EORTC study 30986. J Clin Oncol. 27:5634–5639. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Calabrò F, Lorusso V, Rosati G, Manzione
L, Frassineti L, Sava T, Di Paula ED, Alonso S and Sternberg CN:
Gemcitabine and paclitaxel every 2 weeks in patients with
previously untreated urothelial carcinoma. Cancer. 115:2652–2659.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hussain SA, Stocken DD, Riley P, Palmer
DH, Peake DR, Geh JI, Spooner D and James ND: A phase I/II study of
gemcitabine and fractionated cisplatin in an outpatient setting
using a 21-day schedule in patients with advanced and metastatic
bladder cancer. Br J Cancer. 91:844–849. 2004.PubMed/NCBI
|
|
14
|
Bambury RM, Benjamin DJ, Chaim JL, Zabor
EC, Sullivan J, Garcia-Grossman IR, Regazzi AM, Ostrovnaya I,
Apollo A, Xiao H and Voss: The safety and efficacy of single-agent
pemetrexed in platinum-resistant advanced urothelial carcinoma: A
large single-institution experience. Oncologist. 20:508–515. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bennouna J, Delord JP, Campone M and
Nguyen L: Vinflunine: A new microtubule inhibitor agent. Clin
Cancer Res. 14:1625–1632. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Culine S, Theodore C, De Santis M, Bui B,
Demkow T, Lorenz J, Rolland F, Delgado FM, Longerey B and James N:
A phase II study of vinflunine in bladder cancer patients
progressing after first-line platinum-containing regimen. Br J
Cancer. 94:1395–1401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vaughn DJ, Srinivas S, Stadler WM, Pili R,
Petrylak D, Sternberg CN, Smith DC, Ringuette S, de Wit E, Pautret
V, et al: Vinflunine in platinum-pretreated patients with locally
advanced or metastatic urothelial carcinoma: Results of a large
phase 2 study. Cancer. 115:4110–4117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bellmunt J, Théodore C, Demkov T, Komyakov
B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A,
Karyakin O, et al: Phase III trial of vinflunine plus best
supportive care compared with best supportive care alone after a
platinum-containing regimen in patients with advanced transitional
cell carcinoma of the urothelial tract. J Clin Oncol. 27:4454–4461.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bellmunt J, Fougeray R, Rosenberg JE, von
der Maase H, Schutz FA, Salhi Y, Culine S and Choueiri TK:
Long-term survival results of a randomized phase III trial of
vinflunine plus best supportive care versus best supportive care
alone in advanced urothelial carcinoma patients after failure of
platinum-based chemotherapy. Ann Oncol. 24:1466–1472. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Castellano D, Puente J, de Velasco G,
Chirivella I, López-Criado P, Mohedano N, Fernández O,
García-Carbonero I, González MB and Grande E: Safety and
effectiveness of vinflunine in patients with metastatic
transitional cell carcinoma of the urothelial tract after failure
of one platinum-based systemic therapy in clinical practice. BMC
Cancer. 14:7792014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Medioni J, Guillot A, Spaeth D, Di Palma M
and Theodore C: Historical data in real life from patients treated
by vinflunine for an advanced or metastatic urothelial carcinoma:
Results of the CURVE study. Eur J Cancer. 49:S646–S647. 2013.
|
|
22
|
Hegele A, De Geeter P, Goebell P, Matz U,
De Schultz W and Retz M: Vinflunine in routine practice for the
treatment of advanced or metastatic urothelial cell carcinoma in
Germany. Eur J Cancer. 49:669. 2013.
|
|
23
|
Bellmunt J, Orsola A, Maldonado X and
Kataja V; ESMO Guidelines Working Group: Bladder cancer: ESMO
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 21(Suppl 5): v134–v136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Plimack ER, Bellmunt J, Gupta S, Berger R,
Montgomery RB, Heath K, Juco J, Emancipator K, Pathiraja K,
Lunceford JK, et al: Pembrolizumab (MK-3475) for advanced
urothelial cancer: Updated results and biomarker analysis from. J
Clin Oncol. 33:45022015.
|
|
25
|
Hoffman-Censits JH, Grivas P, Van Der
Heijden MS, Dreicer R, Loriot Y, Retz M, Vogelzang NJ, Perez-Gracia
JL, Rezazadeh A, Bracarda S, et al: IMvigor 210, a phase II trial
of atezolizumab (MPDL3280A) in platinum-treated locally advanced or
metastatic urothelial carcinoma (mUC). Genitourinary cancer
meeting: 2016 Genitourinary cancers symposium. Welcome and general
session 4: Immunotherapy for urothelial carcinoma. J Clin Oncol.
34(Suppl 2): 3552016. View Article : Google Scholar
|
